section name header

Pronunciation

nal-OX-one

Classifications

Therapeutic Classification: antidotes (for opioids)

Pharmacologic Classification: opioid antagonists

Indications

REMS


Unlabeled Use:

Action

  • Competitively blocks the effects of opioids, including CNS and respiratory depression, without producing any agonist (opioid-like) effects.
Therapeutic effects:
  • Reversal of signs of opioid excess.

Pharmacokinetics

Absorption: Well absorbed after IM or SUBQ administration. IV administration results in complete bioavailability. Rapidly absorbed from nasal mucosa.

Distribution: Rapidly distributed to tissues. Crosses the placenta.

Metabolism/Excretion: Metabolized by the liver.

Half-Life: IM, IV, or SUBQ: 30–90 min (up to 3 hr in neonates); Intranasal: 2 hr.

Time/Action Profile

(reversal of opioid effects)

ROUTEONSETPEAKDURATION
IV1–2 minunknown45 min
IM, SUBQ2–5 minunknown>45 min
Intranasal8–13 minunknownunknown



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Route/Dosage

Postoperative Opioid-Induced Respiratory Depression

Opioid-Induced Respiratory Depression During Chronic (>1 wk) Opioid Use

Overdose of Opioids

Opioid-Induced Pruritus

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

IV Administration:

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Evzio, Kloxxado, Narcan, Rextovy, Rezenopy, Rivive, Zimhi

Code

NDC Code